Condition: Alveolar Soft Part Sarcoma · Leiomyosarcoma · Synovial Sarcoma · Sponsor: Advenchen Laboratories, LLC
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.
This description comes directly from the study's public registry record.
Shiying Clinical Trial Manager · 8055301550 · Shiyings@advenchen.com
Judy Clinical Trial Manager · 8055301550 · judyc@advenchen.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Completed |
| University of California Los Angeles | Los Angeles, California, United States | Completed |
| Sarcoma Oncology Center | Santa Monica, California, United States | Recruiting |
| Stanford Medicine Cancer Institute | Stanford, California, United States | Completed |
| University of Colorado Denver | Aurora, Colorado, United States | Completed |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Completed |
| University of Miami Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Completed |
| Northwestern University | Chicago, Illinois, United States | Completed |
| University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan, United States | Completed |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Completed |
| Washington University St. Louis | St Louis, Missouri, United States | Completed |
| Columbia University Medical Center | New York, New York, United States | Withdrawn |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03016819